Add BrightSurf on Google Email

Coping with schizophrenia, when emotions can be too much

People with schizophrenia struggle to regulate their emotions as negative feelings intensify, unlike healthy individuals who employ coping strategies at higher emotional states. Researchers found that those with schizophrenia tend to be less likely to engage in emotion regulation efforts when emotions are extremely high.

SourceUniversity of Georgia·JournalEuropean Archives of Psychiatry and Clinical Neuroscience·DateDec 8, 2021

Choosing the 'best' embryo in IVF

Researchers found that selecting the embryo with the lowest predicted risk score reduces disease risk more effectively than eliminating high-scoring embryos. However, polygenic embryo screening offers no guarantees about a baby's health and has limited effectiveness depending on factors like ancestry and age.

SourceThe Hebrew University of Jerusalem·JournaleLife·TypeData/statistical analysis·DateOct 12, 2021

Researchers improve method to map brain cell connectivity

Scientists have developed an improved technique to trace brain connections between neurons in zebrafish using vesicular stomatitis virus (VSV), enabling the visualization of connected neurons up to five days after infection. This breakthrough could provide insights into brain network connectivity repair after injury or disease.

SourceVirginia Tech·JournalFrontiers in Neuroanatomy·TypeExperimental study·DateOct 6, 2021

October issues of American Psychiatric Association journals cover diabetes and depression connection; schizophrenia treatment; mental health of community college students and more

The American Psychiatric Association journals feature research on the mental health of community college students, diabetes, depression, and schizophrenia treatment. The findings extend and validate previous studies relevant to clinical psychiatry.

SourceAmerican Psychiatric Association·JournalAmerican Journal of Psychiatry·DateOct 1, 2021

Synaptic dysfunction in schizophrenia

A new study found that schizophrenia is associated with a loss of excitation but an increase in inhibition, resulting in hallucinations. The researchers used EEG data from 107 participants to demonstrate decreased synaptic gain, which may guide pharmacological and neurostimulation treatments.

SourceElsevier·JournalBiological Psychiatry·TypeImaging analysis·DateSep 23, 2021

Research reveals drug targets for memory enhancement

A Bristol-led research team has identified specific receptors for the neurotransmitter acetylcholine that re-route information flowing through memory circuits in the hippocampus. The discovery holds promise for developing new, safer treatments for conditions like Alzheimer's disease and schizophrenia.

SourceUniversity of Bristol·JournalNature Communications·TypeObservational study·DateSep 16, 2021

Schizophrenia study suggests advanced genetic scorecard cannot predict a patient’s fate

A Mount Sinai study found that polygenic risk scores were no better at predicting worsening symptoms than written reports in schizophrenia patients. The results raise questions about the use of polygenic risk scores in real-world situations, suggesting a doctor's report may be an untapped source of predictive information.

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalNature Medicine·TypeExperimental study·DateSep 6, 2021

A “helping hand”: Intervention for early cancer screening in patients with mental illness

Researchers from Okayama University conducted a randomized trial to assess the benefits of interventions for early cancer screening in patients with schizophrenia. The study found that 47.1% of counseled patients underwent colorectal cancer screening, compared to 11.8% of those receiving only usual treatment.

SourceOkayama University·JournalActa Psychiatrica Scandinavica·TypeRandomized controlled/clinical trial·DateAug 23, 2021

Advanced glycation end products and cognitive impairment in schizophrenia

A study found that plasma pentosidine levels, a marker of advanced glycation end products, were significantly associated with impaired processing speed in schizophrenia patients. The results suggest that reducing AGEs may contribute to improving cognitive function and promoting recovery in patients with schizophrenia.

SourceTokyo Metropolitan Institute of Medical Science·JournalPLOS ONE·TypeData/statistical analysis·DateAug 12, 2021

A machine learning approach for predicting risk of schizophrenia using a blood test

Researchers at Baylor College of Medicine developed a machine learning algorithm that analyzes DNA methylation patterns in blood samples to identify individuals with schizophrenia. The study achieved an 80% accuracy rate and identified epigenetic markers that differ between people diagnosed with the condition and those without it.

SourceBaylor College of Medicine·JournalTranslational Psychiatry·TypeExperimental study·DateAug 3, 2021

Study helps to deeper understanding of brain dysfunctions in patients with schizophrenia

A study using protein mapping reveals that abnormal glutamate levels in the brains of schizophrenic patients can lead to oxidative stress and apoptosis in neurons, while oligodendrocytes display different responses. This knowledge may contribute to the development of more targeted treatments for schizophrenia.

SourceFundação de Amparo à Pesquisa do Estado de São Paulo·JournalEuropean Archives of Psychiatry and Clinical Neuroscience·DateJun 7, 2021

Vitamin B6 deficiency enhances the noradrenergic system, leading to behavioral deficits

A study found that Vitamin B6 deficiency is associated with social deficits, cognitive impairment, and hyperactivated noradrenergic systems in mice. Supplementing the brain with Vitamin B6 improved these abnormalities, suggesting a potential therapeutic strategy for schizophrenia patients with Vitamin B6 deficiency.

SourceTokyo Metropolitan Institute of Medical Science·JournalTranslational Psychiatry·DateMay 25, 2021

Genetic predisposition to schizophrenia may increase risk of psychosis from cannabis use

A new study published in Translational Psychiatry reveals that individuals with high genetic predisposition to schizophrenia are disproportionately affected by cannabis use, experiencing a 60% higher risk of psychotic experiences. Cannabis users, compared to non-users, have higher rates of psychotic experiences across the board.

SourceCentre for Addiction and Mental Health·JournalTranslational Psychiatry·DateApr 13, 2021

Pilot study finds evidence of bartonella infection in schizophrenia patients

A pilot study from North Carolina State University and the University of North Carolina at Chapel Hill found evidence of Bartonella infection in the blood of people with schizophrenia and schizoaffective disorder. The study suggests a potential link between Bartonella infection and neuropsychiatric disease, particularly schizophrenia.

SourceNorth Carolina State University·JournalVector-Borne and Zoonotic Diseases·DateMar 23, 2021

Rare mutations may have big impact on schizophrenia pathology

Researchers identified somatic gene mutations in brain cells of people with schizophrenia that disrupted synaptic function and affected proteins critical for neural signaling. The study found that these rare mutations could contribute to the disease's neuropathology, particularly in genes associated with glutamate receptor function.

SourceElsevier·JournalBiological Psychiatry·DateMar 9, 2021

Researchers identify characteristics of highest utilizers for mental health hospital services

A new study by researchers at the University of Texas Health Science Center at Houston found that dropping out of high school, having schizophrenia, or a co-occurring personality disorder increases the likelihood of someone becoming a high utilizer. The research used machine learning to analyze deidentified electronic health record dat...

SourceUniversity of Texas Health Science Center at Houston·JournalJournal of Health Care for the Poor and Underserved·DateFeb 26, 2021

Specific genes in placenta may predict size of baby's brain and risk for schizophrenia

A genetic scoring study published in PNAS found that specific genes in the placenta can predict a baby's brain size at birth and its rate of cognitive development, which may lead to schizophrenia later in life. The study suggests that targeting placental health may reduce schizophrenia risk, particularly in males.

SourceUniversity of North Carolina Health Care·JournalProceedings of the National Academy of Sciences·DateFeb 8, 2021